Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Blood (2017) 130 (Supplement 1): 323.

https://doi.org/10.1182/blood.V130.Suppl_1.323.323

Published: 2017

Journal Articles

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Blood (2016) 128 (22): 3128.

https://doi.org/10.1182/blood.V128.22.3128.3128

Published: 2016

Journal Articles

A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)

Eric W Van Den Neste, MD PhD, Marc Andre, MD, Thomas Gastinne, MD, Aspasia Stamatoullas, MD, Corinne Haioun, MD PhD, Amine Belhabri, MD, Oumedaly Reman, MD, Olivier Casasnovas, MD, Herve Ghesquieres, MD PhD, Gregor Verhoef, MD PhD, Marie-José Claessen, Hélène A Poirel, Marie-Christine Copin, Romain Dubois, Peter Vandenberghe, MD PhD, Ioanna-Andrea Stoian, Anne Ségolène Cottereau, MD, Laurent Knoops, MD PhD, Franck Morschhauser

Blood (2016) 128 (22): 4160.

https://doi.org/10.1182/blood.V128.22.4160.4160

Published: 2016

Journal Articles

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Claire N. Harrison, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD PhD, Francisco Cervantes, Mark M. Jones, MD, Kang Sun, PhD, Laurence Descamps, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Tiziano Barbui, MD

Blood (2015) 126 (23): 59.

https://doi.org/10.1182/blood.V126.23.59.59

Published: 2015

Journal Articles

Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors

Lorraine Springuel, Tekla Hornakova, Elisabeth Losdyck, Fanny Lambert, Emilie Leroy, Stefan N. Constantinescu, Elisabetta Flex, Marco Tartaglia, Laurent Knoops, Jean-Christophe Renauld

Blood (2014) 124 (26): 3924–3931.

https://doi.org/10.1182/blood-2014-05-576652

Published: 2014

Includes: Supplemental data

Journal Articles

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Blood (2014) 124 (21): 1823.

https://doi.org/10.1182/blood.V124.21.1823.1823

Published: 2014

Journal Articles

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

Francesco Passamonti, Margherita Maffioli, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Tiziano Barbui, Domenica Caramazza, Lisa Pieri, Elisa Rumi, Heinz Gisslinger, Laurent Knoops, Jean Jaques Kiladjian, Barbara Mora, Norbert Hollaender, Cristiana Pascutto, Claire Harrison, Mario Cazzola

Blood (2014) 123 (12): 1833–1835.

https://doi.org/10.1182/blood-2013-12-544411

Published: 2014

Journal Articles

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Francisco Cervantes, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andres Sirulnik, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S. Hunter, Richard S. Levy, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Claire N. Harrison, Laurent Knoops, Heinz Gisslinger

Blood (2013) 122 (25): 4047–4053.

https://doi.org/10.1182/blood-2013-02-485888

Published: 2013

Includes: Supplemental data

Journal Articles

Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts

Francesco Passamonti, MD, Margherita Maffioli, MD, Francisco Cervantes, MD, PhD, Alessandro M. Vannucchi, MD, PhD, Enrica Morra, MD, Tiziano Barbui, MD, Caramazza Domenica, MD, Elisa Rumi, MD, Gisslinger Heinz, Laurent Knoops, MD, PhD, Barbara Mora, MD, Norbert Hollaender, PhD, Margaret Squier, MD, PhD, Cristiana Pascutto, Claire N Harrison, DM, FRCP, FRCPath, Mario Cazzola, MD

Blood (2013) 122 (21): 4066.

https://doi.org/10.1182/blood.V122.21.4066.4066

Published: 2013

Journal Articles

The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT)

Matthew Squires, PhD, Claire N Harrison, DM, FRCP, FRCPath, Giovanni Barosi, MD, Alessandro M Vannucchi, MD, Tiziano Barbui, MD, Heinz Gisslinger, Francesco Passamonti, MD, Haifa Kathrin Al-Ali, MD, Jean-Jacques Kiladjian, MD, PhD, Mahtab T. Marker, PhD, Estella T. Mendelson, BSRN, MBA, Viktoriya Stalbovskaya, PhD, Francisco Cervantes, MD, PhD, Laurent Knoops, MD, PhD

Blood (2013) 122 (21): 4070.

https://doi.org/10.1182/blood.V122.21.4070.4070

Published: 2013

Journal Articles

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Francisco Cervantes, MD, Jean-Jacques Kiladjian, MD, PhD, Dietger Niederwieser, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Mari McQuity, RN, MPH, Deborah S. Hunter, PhD, Richard S. Levy, MD, Francesco Passamonti, MD, Tiziano Barbui, MD, Giovanni Barosi, MD, Heinz Gisslinger, MD, Alessandro M. Vannucchi, MD, Laurent Knoops, MD, PhD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 801.

https://doi.org/10.1182/blood.V120.21.801.801

Published: 2012

Journal Articles

Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT)

Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Haifa Kathrin Al-Ali, MD, Giovanni Barosi, MD, Claire N Harrison, DM FRCP FRCPath, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Matthew Squires, PhD, Timothy Burn, PhD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, Tiziano Barbui, MD, Heinz Gisslinger, MD, Jean-Jacques Kiladjian, MD, PhD

Blood (2012) 120 (21): 802.

https://doi.org/10.1182/blood.V120.21.802.802

Published: 2012

Journal Articles

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes

Christian Pecquet, Carmen C. Diaconu, Judith Staerk, Michael Girardot, Caroline Marty, Yohan Royer, Jean-Philippe Defour, Alexandra Dusa, Rodolphe Besancenot, Stephane Giraudier, Jean-Luc Villeval, Laurent Knoops, Pierre J. Courtoy, William Vainchenker, Stefan N. Constantinescu

Blood (2012) 119 (20): 4625–4635.

https://doi.org/10.1182/blood-2011-08-372524

Published: 2012

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy

Claire N. Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD, PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD, PhD, Roger J. Waltzman, MD, Estella T. Mendelson, BSRN, MBA, Xiaolei Zhou, Catherine Copley-Merriman, Deborah S. Hunter, PhD, Richard S. Levy, MD, Francisco Cervantes, MD, PhD, Francesco Passamonti, MD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD

Blood (2011) 118 (21): 795.

https://doi.org/10.1182/blood.V118.21.795.795

Published: 2011

Journal Articles

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

Claire N. Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD, PhD, Heinz Gisslinger, MD, Dietger Niederwieser, MD, Francesco Passamonti, MD, Roger J. Waltzman, MD, Norbert Hollaender, PhD, Deborah S. Hunter, PhD, Richard S. Levy, MD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, PhD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD

Blood (2011) 118 (21): 279.

https://doi.org/10.1182/blood.V118.21.279.279

Published: 2011

Journal Articles

A Ruxolitinib Individual Supply Program for Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Giovanni Barosi, MD, Francisco Cervantes, MD, PhD, Dina Ben-Yehuda, MD, Panagiotis Panagiotidis, Jose Ricardo Perez, MD, Nancy D. Orlando-Harper, Nicolas Martin, MS, Wolfgang Willenbacher, MD, Emilio Ojeda, MD, PhD, Heinz Gisslinger, MD, Laurent Knoops, MD, PhD

Blood (2011) 118 (21): 5170.

https://doi.org/10.1182/blood.V118.21.5170.5170

Published: 2011

Journal Articles

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia

Maria Kleppe, Jean Soulier, Vahid Asnafi, Nicole Mentens, Tekla Hornakova, Laurent Knoops, Stefan Constantinescu, François Sigaux, Jules P. Meijerink, Peter Vandenberghe, Marco Tartaglia, Robin Foa, Elizabeth Macintyre, Torsten Haferlach, Jan Cools

Blood (2011) 117 (26): 7090–7098.

https://doi.org/10.1182/blood-2010-10-314286

Published: 2011

Journal Articles

Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study

Blood (2010) 116 (21): 440.

https://doi.org/10.1182/blood.V116.21.440.440

Published: 2010

Journal Articles

miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets

Michael Girardot, Christian Pecquet, Siham Boukour, Laurent Knoops, Augustin Ferrant, William Vainchenker, Stéphane Giraudier, Stefan N. Constantinescu

Blood (2010) 116 (3): 437–445.

https://doi.org/10.1182/blood-2008-06-165985

Published: 2010

Includes: Supplemental data

Journal Articles

ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon

Tekla Hornakova, Sabina Chiaretti, Muriel M. Lemaire, Robin Foà, Raouf Ben Abdelali, Vahid Asnafi, Marco Tartaglia, Jean-Christophe Renauld, Laurent Knoops

Blood (2010) 115 (16): 3287–3295.

https://doi.org/10.1182/blood-2009-09-245498

Published: 2010

NARROW

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts

The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT)

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT)

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes

Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

A Ruxolitinib Individual Supply Program for Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia

Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study

miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets

ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only